We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
California-based Avanir Pharmaceuticals announced that the U.S. FDA has informed the company it is extending the review period of its new drug application (NDA) for Neurodex for an additional 90 days.
An Austrian court has ruled for drug firm Novogen in a patent dispute over the company's menopause symptom relief product Promensil, the Sydney, Australia-based drugmaker announced.
Japan-based Toyama Chemical has begun Phase I clinical trials of T-5224, its proprietary drug candidate for the treatment of rheumatoid
arthritis (RA).
BioMachines Inc. has announced the signing of an exclusive distribution agreement with CapitalBio Corporation of Beijing, China. With the signing of this agreement, BioMachines has expanded its sales channel beyond North America and Europe and into China, Taiwan and Hong Kong.
CV Therapeutics, Inc. has acquired rights to ranolazine in Asia following an amendment to its existing licensing agreement with Roche Palo Alto LLC adding rights to Japan, China, Korea and other Asian markets.
A fresh battle whose outcome will greatly affect the cost of drugs in Kenya has erupted between multinational pharmaceutical companies and independent drug distributors and international aid organizations.
ISTA Pharmaceuticals, Inc., announced today it has entered into a definitive agreement with several institutional investors to issue $40 million aggregate principal amount of senior subordinated convertible notes.